Mineralys Accounts Payable vs Net Working Capital Analysis
| MLYS Stock | 11.87 0.73 5.79% |
Mineralys Therapeutics, financial indicator trend analysis is infinitely more than just investigating Mineralys Therapeutics, recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Mineralys Therapeutics, is a good investment. Please check the relationship between Mineralys Therapeutics, Accounts Payable and its Net Working Capital accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mineralys Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
Accounts Payable vs Net Working Capital
Accounts Payable vs Net Working Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Mineralys Therapeutics, Accounts Payable account and Net Working Capital. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Mineralys Therapeutics,'s Accounts Payable and Net Working Capital is 0.46. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Mineralys Therapeutics, Common, assuming nothing else is changed. The correlation between historical values of Mineralys Therapeutics,'s Accounts Payable and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Mineralys Therapeutics, Common are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Accounts Payable i.e., Mineralys Therapeutics,'s Accounts Payable and Net Working Capital go up and down completely randomly.
Correlation Coefficient | 0.46 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Accounts Payable
An accounting item on the balance sheet that represents Mineralys Therapeutics, obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Mineralys Therapeutics, are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Net Working Capital
Most indicators from Mineralys Therapeutics,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Mineralys Therapeutics, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mineralys Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. At this time, Mineralys Therapeutics,'s Selling General Administrative is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 769.5 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 130.7 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 27K | 1.7M | 1.9M | 2.0M | Depreciation And Amortization | 18.7M | 228.5K | 167.9K | 159.5K |
Mineralys Therapeutics, fundamental ratios Correlations
Click cells to compare fundamentals
Mineralys Therapeutics, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.